July 13 (Reuters) - The U.S. Food and Drug Administrationhas approved AstraZeneca Plc's drug, Iressa, as afirst-line treatment for a common form of lung cancer.
The drug was previously approved for use in non-small celllung cancer patients only after they did not respond tochemotherapy.
The FDA said on Tuesday the approval was based on resultsfrom a trial of 106 patients with previously untreated non-smallcell lung cancer. (http://1.usa.gov/1Sjw5eo) (Reporting by Amrutha Penumudi in Bengaluru; Editing by KirtiPandey)
Astrazeneca (AZN)
